News Image

Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results

Provided By GlobeNewswire

Last update: May 12, 2025

Phase 2 APEX trial of APG777 in atopic dermatitis advancing with interim Part A 16-week data expected in mid-2025 and Part B actively enrolling

First patient dosed in Phase 1b trial of APG777 in mild-to-moderate asthma with readout expected in 1H 2026

Read more at globenewswire.com

APOGEE THERAPEUTICS INC

NASDAQ:APGE (6/12/2025, 8:00:01 PM)

After market: 41.86 0 (0%)

41.86

-0.58 (-1.37%)



Find more stocks in the Stock Screener

Follow ChartMill for more